HOME >> BIOLOGY >> NEWS
Closing in on treatment for Charcot-Marie-Tooth disease?

Charcot-Marie-Tooth (CMT) is a hereditary disorder of the peripheral nervous system that strikes 1 person in every 2500. Increasing debilitation of the muscles ultimately leads to their disappearance in the lower legs, feet and hands. Now, researchers from VIB (the Flanders Interuniversity Institute for Biotechnology) have discovered a piece of the molecular puzzle of this disease. Two small 'heat shock' proteins turn out to be crucial - faults in the coding genes lead to the disease. Additional research has shown that these proteins play an important role in many other neurodegenerative disorders as well. This research moves us a step closer to the development of new therapies.

CMT, a serious disorder without a cure

CMT, the most common hereditary disorder of the peripheral nervous system, leads to debilitation of the muscles in the lower legs, feet and hands. The clinical picture is extremely variable, but older patients sometimes require a wheelchair. Today, only supportive treatment is available; there are still no effective therapies to retard or stop the progress of the disease. More insight into the molecular processes of this disease is essential for diagnosis and potential treatment. And exploration of the genes involved is a crucial step in this.

VIB research findings

Joy Irobi and her colleagues - under the direction of Vincent Timmerman and Peter De Jonghe of the Department of Molecular Genetics, University of Antwerp - are concentrating on the genetic and biological study of hereditary disorders of the peripheral nervous system. The largest cells in our body, our peripheral neurons can be 1 meter long in bundles of nerve fibers extending from the spinal cord to the feet.

Recently, the researchers in Antwerp have found mutations in the genetic code of two small 'heat shock' proteins (HSPs) in a number of people with CMT. In stress situations, cells produce HSPs that act as 'chaperones', stabilizing
'"/>

Contact: Ann Van Gysel
ann.vangysel@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
7-May-2004


Page: 1 2

Related biology news :

1. Closing in on the cellular culprits of schizophrenia
2. Researchers Closing In On Gene For Paralytic Disorder
3. Leader in cancer treatment and prevention research honored
4. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
5. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
6. New treatment for fibromyalgia
7. The impact of genetic variations on the treatment of early rheumatoid arthritis
8. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
9. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
10. Colleagues to recognize research leadership in cancer detection, prevention and treatment
11. New view of leukemia cells identifies best treatment options, Stanford researchers say

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... , ... December 06, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... Axovant Sciences Ltd. (NYSE: AXON ... treatment of dementia, today announced that data on the ... disease will be presented at the 2016 Clinical Trials ... 2016 in San Diego . Intepirdine ... and complex measures of activities of daily living (ADLs) ...
Breaking Biology Technology:
Cached News: